logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Inotersen (Ionis TTRRx) for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) – first line

< Back

Inotersen (Ionis TTRRx) for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) – first line

Drugs

Neurology and Neurosurgery

March 2017


Inotersen is a new drug to treat hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), which is a rare disease caused by the abnormal build-up of proteins in the tissues of the body. Inotersen is delivered by injection under the skin. It stops a protein called transthyretin being made, and therefore stops it from building-up in body tissues.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts